{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-344594","form_type":"8-K","ticker":"TSHA","cik":"0001806310","company_name":"Taysha Gene Therapies, Inc.","filed_at":"2026-08-11T20:05:48+00:00","discovered_at":"2026-08-11T20:07:00.452790+00:00","generated_at":"2026-08-11T20:07:11.311379+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Taysha Q2 2026 net loss $46.6M; TSHA-102 pivotal dosing complete, $230M raised","bullets":["Net loss $46.6M ($0.13/share) vs $26.9M ($0.09) in Q2 2025; R&D expenses $38.6M vs $20.1M.","Completed dosing in REVEAL pivotal (N=17) and ASPIRE (N=4) trials for TSHA-102 in Rett syndrome; topline interim data expected 1H 2027.","TSHA-102 generally well tolerated with no severe treatment-related SAEs or DLTs across 33 patients as of Aug 2026 cutoff.","Completed $230M follow-on offering; cash and equivalents $455.4M as of June 30, 2026, runway into 2H 2028.","Expanded Catalent partnership for commercial manufacturing; appointed Mike Johannesen as Chief Legal Officer in June 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-344594","json":"https://secwatch.observer/filing/0001193125-26-344594.json","markdown":"https://secwatch.observer/filing/0001193125-26-344594.md","text":"https://secwatch.observer/filing/0001193125-26-344594.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806310/000119312526344594/0001193125-26-344594-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806310/000119312526344594/d161230d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-11T20:07:11.311379+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}